| Tianyu Qin,Gang Chen. Recent advances in targeted therapy for ovarian cancer. Oncol Transl Med, 2022, 8: 28-35. |
| Recent advances in targeted therapy for ovarian cancer |
| Recent advances in targeted therapy for ovarian cancer |
| Received:February 07, 2022 Revised:March 09, 2022 |
| DOI：10.1007/s10330-022-0557-7 |
| 中文关键词: ovarian cancer; targeted therapy; anti-angiogenesis; poly-(ADP)-ribose polymerase (PARP) inhibitor; immune checkpoint inhibitor (ICI); clinical trial |
| 英文关键词: ovarian cancer; targeted therapy; anti-angiogenesis; poly-(ADP)-ribose polymerase (PARP) inhibitor; immune checkpoint inhibitor (ICI); clinical trial |
| 基金项目: |
| Author Name | Affiliation | Postcode | | Tianyu Qin | National Clinical Research Center for Gynecology and Obstetrics
Cancer Biology Research Center
Department of Gynecology and Obstetrics
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China | 430030 | | Gang Chen* | National Clinical Research Center for Gynecology and Obstetrics
Cancer Biology Research Center
Department of Gynecology and Obstetrics
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China | 430030 |
|
| Hits: 5141 |
| Download times: 6223 |
| 中文摘要: |
| The global burden of ovarian cancer is gradually increasing while patients still suffer from relatively limited
treatment options. With recent advances in the decoding of the molecular landscape of ovarian cancer,
more options in targeted strategy were offered and can therefore be tailored in different clinical settings for
individual patient. Targeting of the abnormal angiogenesis process is the first significant clinical breakthrough
which revolutionized the treatment of advanced ovarian cancer, followed by the advent of poly-(ADP)-ribose
polymerase (PARP) inhibitors. These two strategies represented by bevacizumab and olaparib respectively
underwent tests of numerous clinical trials. In recent years, immune checkpoint inhibitors (ICIs) have been
incorporated into the blueprint of ovarian cancer treatment though the effectiveness still left much to be
desired. Herein, we systematically outlined recent advances in targeted therapy for ovarian cancer and
summarized the landmark clinical trials for each targeted therapy including angiogenesis inhibitors, PARP
inhibitors and ICIs. |
| 英文摘要: |
| The global burden of ovarian cancer is gradually increasing while patients still suffer from relatively limited
treatment options. With recent advances in the decoding of the molecular landscape of ovarian cancer,
more options in targeted strategy were offered and can therefore be tailored in different clinical settings for
individual patient. Targeting of the abnormal angiogenesis process is the first significant clinical breakthrough
which revolutionized the treatment of advanced ovarian cancer, followed by the advent of poly-(ADP)-ribose
polymerase (PARP) inhibitors. These two strategies represented by bevacizumab and olaparib respectively
underwent tests of numerous clinical trials. In recent years, immune checkpoint inhibitors (ICIs) have been
incorporated into the blueprint of ovarian cancer treatment though the effectiveness still left much to be
desired. Herein, we systematically outlined recent advances in targeted therapy for ovarian cancer and
summarized the landmark clinical trials for each targeted therapy including angiogenesis inhibitors, PARP
inhibitors and ICIs. |
|
View Full Text
Download reader HTML全文 |
| Close |